Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
APRE Aprea Therapeutics
0.474-0.003-0.63%
Close
01/27 16:00 ET
0.498+0.024+4.98%
Post Mkt Price 01/27 19:54 ET
High
0.490
Open
0.490
Turnover
29.84K
Low
0.469
Pre Close
0.477
Volume
62.46K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Aprea Therapeutics: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8 | Aprea Therapeutics, Inc. (0001781983) (Filer)
Aprea Therapeutics: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8 | Aprea Therapeutics, Inc. (0001781983) (Filer)
Aprea Therapeutics: Information required of institutional investment managers pursuant to Section 13(f)
3 | Aprea Therapeutics, Inc. (0001781983) (Issuer)
Aprea Therapeutics: Information required of institutional investment managers pursuant to Section 13(f)
3 | Aprea Therapeutics, Inc. (0001781983) (Issuer)
Aprea Therapeutics: Information required of institutional investment managers pursuant to Section 13(f)
3 | Aprea Therapeutics, Inc. (0001781983) (Issuer)
Aprea Therapeutics: Information required of institutional investment managers pursuant to Section 13(f)
3 | Aprea Therapeutics, Inc. (0001781983) (Issuer)
Aprea Therapeutics: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8 | Aprea Therapeutics, Inc. (0001781983) (Filer)
Aprea Therapeutics: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8 | Aprea Therapeutics, Inc. (0001781983) (Filer)
Aprea Therapeutics: Registration statement for specified transactions by certain issuers
S-3 | Aprea Therapeutics, Inc. (0001781983) (Filer)
Aprea Therapeutics: Information required of institutional investment managers pursuant to Section 13(f)
3 | Aprea Therapeutics, Inc. (0001781983) (Issuer)
Company Overview
More
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Boston, MA.
CEO： Dr. Oren Gilad, PhD
Market： NASDAQ
Listing Date： 10/03/2019
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet